PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Primary objective to determine the maximal tolerated (MTD) of dasatinib in combination with
paclitaxel and carboplatin during the first cycle of treatment.
Secondary objectives to describe the toxicity of this combination of therapy; to describe the
pharmacokinetics and pharmacodynamics parameters related to this combination; to describe the
clinical activity as defined as the response rate (complete and partial response rate) and
progression-free survival > 6 month; to compare the SRC pathway microarray signature in pre
and post-treatment cancer specimens; to evaluate SRC pathway downstream substrates, FAX,
paxcillin, and CRK-L in pre and post-treatment cancer specimens.